UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach

Translational lung cancer research, 2013-04, Vol.2 (2), p.142-151

2013

Volltextzugriff (PDF)

Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer

ESMO open, 2017, Vol.2 (3), p.e000219-e000219, Article e000219

2017

Volltextzugriff (PDF)

miR-124 as a Liquid Biopsy Prognostic Biomarker in Small Extracellular Vesicles from NSCLC Patients

International journal of molecular sciences, 2023-07, Vol.24 (14), p.11464

2023

Volltextzugriff (PDF)

Cancer and acute cardiovascular diseases: team work to transform the clinical practice

European heart journal. Acute cardiovascular care, 2021-10, Vol.10 (8), p.840-842

2021

Volltextzugriff (PDF)

MKP1 repression is required for the chemosensitizing effects of NF-κB and PI3K inhibitors to cisplatin in non-small cell lung cancer

Cancer letters, 2009-12, Vol.286 (2), p.206-216

2009

Volltextzugriff (PDF)

PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis

Journal of clinical medicine, 2021-10, Vol.10 (19), p.4583

2021

Volltextzugriff (PDF)

Epidemiology and characteristics of febrile neutropenia in oncology patients from Spanish tertiary care hospitals: PINNACLE study

Molecular and clinical oncology, 2015-05, Vol.3 (3), p.725-729

2015

Volltextzugriff (PDF)

Expert consensus to optimize the management of older adult patients with advanced EGFR-mutated non-small cell lung cancer

Clinical & translational oncology, 2023-11, Vol.25 (11), p.3139-3151

2023

Volltextzugriff (PDF)

Cardiovascular toxicity of checkpoint inhibitors: review of associated toxicity and design of the Spanish Immunotherapy Registry of Cardiovascular Toxicity

Clinical & translational oncology, 2023-11, Vol.25 (11), p.3073-3085

2023

Volltextzugriff (PDF)

Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug–drug interaction study in patients with ALK + advanced tumors

Cancer chemotherapy and pharmacology, 2021-04, Vol.87 (4), p.475-486

2021

Volltextzugriff (PDF)

Identification of sSIGLEC5 and sLAG3 as New Relapse Predictors in Lung Cancer

Biomedicines, 2022-04, Vol.10 (5), p.1047

2022

Volltextzugriff (PDF)

Abstract CT220: IMpower133: Updated OS and exploratory analyses of first-line (1L) atezolizumab (atezo) + carboplatin (C) + etoposide (E) in extensive-stage SCLC (ES-SCLC)

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT220-CT220

2020

Volltextzugriff (PDF)

Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe

ClinicoEconomics and outcomes research, 2012-01, Vol.4 (default), p.269-275

2012

Volltextzugriff (PDF)

An open-label, multicenter, phase 2 study of the safety and efficacy of navtemadlin (KRT-232) in patients with TP53 wild-type relapsed/refractory small cell lung cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS8600-TPS8600

2022

Volltextzugriff (PDF)

Spatially resolved multi-region transcriptomic subtyping and assessment of gene expression profiles associated with long-term benefit from chemo-immunotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.8594-8594

2023

Volltextzugriff (PDF)

Association of peripheral memory B cell population maintenance and long term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.8551-8551

2023

Volltextzugriff (PDF)

Updated analysis from the ATEZO-BRAIN trial: Atezolizumab plus carboplatin and pemetrexed in patients with advanced nonsquamous non–small cell lung cancer with untreated brain metastases

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9010-9010

2022

Volltextzugriff (PDF)

Multimodal prediction of response to neoadjuvant nivolumab and chemotherapy for surgically resectable stage IIIA non–small cell lung cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.8542-8542

2022

Volltextzugriff (PDF)

Nivolumab + chemotherapy versus chemotherapy as neoadjuvant treatment for resectable stage IIIA NSCLC: Primary endpoint results of pathological complete response (pCR) from phase II NADIM II trial

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.8501-8501

2022

Volltextzugriff (PDF)

MS201944-0170: A phase IIa study to investigate the clinical activity and safety of avelumab in combination with cetuximab plus gemcitabine and cisplatin in patients with advanced squamous NSCLC

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.TPS9123-TPS9123

2019

Volltextzugriff (PDF)

Afectación muscular de un mesotelioma maligno pleural de larga evolución

Archivos de bronconeumología, 2018-05, Vol.54 (5), p.284-285

2018

Volltextzugriff (PDF)

Phase II study of tepotinib in NSCLC patients with MET ex14 mutations

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.9005-9005

2019

Volltextzugriff (PDF)

1 – 25 von 52

Suche als RSS-Feed

Aktive Filter

KollektionMEDLINE

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(52)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy

KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach

Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer

miR-124 as a Liquid Biopsy Prognostic Biomarker in Small Extracellular Vesicles from NSCLC Patients

Cancer and acute cardiovascular diseases: team work to transform the clinical practice

MKP1 repression is required for the chemosensitizing effects of NF-κB and PI3K inhibitors to cisplatin in non-small cell lung cancer

PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis

Epidemiology and characteristics of febrile neutropenia in oncology patients from Spanish tertiary care hospitals: PINNACLE study

Expert consensus to optimize the management of older adult patients with advanced EGFR-mutated non-small cell lung cancer

Cardiovascular toxicity of checkpoint inhibitors: review of associated toxicity and design of the Spanish Immunotherapy Registry of Cardiovascular Toxicity

Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug–drug interaction study in patients with ALK + advanced tumors

Identification of sSIGLEC5 and sLAG3 as New Relapse Predictors in Lung Cancer

Abstract CT220: IMpower133: Updated OS and exploratory analyses of first-line (1L) atezolizumab (atezo) + carboplatin (C) + etoposide (E) in extensive-stage SCLC (ES-SCLC)

Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe

An open-label, multicenter, phase 2 study of the safety and efficacy of navtemadlin (KRT-232) in patients with TP53 wild-type relapsed/refractory small cell lung cancer

Spatially resolved multi-region transcriptomic subtyping and assessment of gene expression profiles associated with long-term benefit from chemo-immunotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC)

Association of peripheral memory B cell population maintenance and long term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial)

Updated analysis from the ATEZO-BRAIN trial: Atezolizumab plus carboplatin and pemetrexed in patients with advanced nonsquamous non–small cell lung cancer with untreated brain metastases

Multimodal prediction of response to neoadjuvant nivolumab and chemotherapy for surgically resectable stage IIIA non–small cell lung cancer

Nivolumab + chemotherapy versus chemotherapy as neoadjuvant treatment for resectable stage IIIA NSCLC: Primary endpoint results of pathological complete response (pCR) from phase II NADIM II trial

MS201944-0170: A phase IIa study to investigate the clinical activity and safety of avelumab in combination with cetuximab plus gemcitabine and cisplatin in patients with advanced squamous NSCLC

Afectación muscular de un mesotelioma maligno pleural de larga evolución

Phase II study of tepotinib in NSCLC patients with MET ex14 mutations

Aktive Filter

Suchergebnisse filtern